Research Article
Grading of Neuroendocrine Carcinomas: Correlation of 68Ga-PET/CT Scan with Tissue Biomarkers
Table 1
Clinical and histological characteristics of NEC patient samples.
| | (%) |
| | Age at diagnosis (years) | | | Mean | 56.6 | | Standard deviation | 13.1 | | Gender | | | Male | 6 (54.5) | | Female | 5 (45.5) | | Site of disease | | | Stomach | 3 (27.2) | | Colorectum | 3 (27.2) | | Pancreas | 5 (45.6) | | Histological classification | | | G3 NET | 6 (54.5) | | G3 NEC | 5 (45.5) | | FDG-PET/CT | | | Positive | 8 (72.7) | | Not done | 3 (27.3) | | 68Ga-PET/CT octreoscan | | | Positive | 4 (36.4) | | Negative | 6 (54.5) | | Not done | 1 (9.1) | | Chemotherapy | | | CDDP | 8 (72.7) | | Carboplatin | 2 (18.1) | | Other | 1 (9.2) | | Best response to first-line chemotherapy | | | PD | 3 (27.2) | | SD | 3 (27.2) | | PR | 5 (45.6) | | Median overall survival, months [range] | 23 [6-70] |
|
|
NEC: neuroendocrine carcinoma; NET: neuroendocrine tumor; G: grade; FDG-PET/CT: fluorodeoxyglucose-positron emission tomography/computerized tomography; 68Ga: Gallium-68; CDDP: cisplatin; PD: progressive disease; SD: stable disease; PR: partial response.
|
